AstraZeneca decides to focus its internal development on CNS candidates in late clinical development phases.
AlzeCure’s current management team is offered the opportunity to further develop innovative therapies for Alzheimer’s and related diseases in the recently started AlzeCure Foundation.
The foundation begins research and development at the Karolinska Institutet Science Park in Solna.
AlzeCure Pharma was founded due to the great commercial potential of the main drug candidates. NeuroRestore is the outcome of in-house research, while Alzstatin derives from AstraZeneca’s research portfolio, where the project was begun on the initiative of AlzeCure’s scientists.
In June, the company carried out its first financing round in the amount of SEK 70 million before issue expenses.
In July, the company carried out its second financing round in the amount of SEK 40 million aimed at financing phase I studies for ACD855.
Preclinical testing of ACD855 was concluded in July.
IMPD (application to commence studies in humans) for ACD855 submitted in October.
Listing takes place on Nasdaq First North Premier in November.
The necessary public authority approvals to begin phase I studies for ACD855 were granted and the company began dosing the first subjects in December.
In March the company initiated a new drug project in the field of pain, TrkA-NAM.
The company was represented at the International Conference on Alzheimer’s & Parkinson’s Diseases where it gave two presentations.
In May the company chose to redirect the drug candidate ACD855 from cognitive dysfunction to an ocular indication and ACD856 became the primary drug candidate for cognitive dysfunction instead.
At the annual general meeting on May 22, the company resolved to issue a warrant program aimed at the company’s Board of Directors.
In December the company obtained the necessary approvals from the regulatory authorities to initiate the first clinical phase I studies for the drug candidate ACD856 within the NeuroRestore platform. The company initiated the study shortly thereafter
In January, the company in-licensed a new project, VR1, which focuses on neuropathic pain and is in the clinical development phase.
Martin Jönsson was appointed to serve as the new Chief Executive Officer on January 8, 2020. Martin has worked in the global pharmaceutical industry for more than 20 years, with extensive experience from various executive positions at both Ferring Pharmaceutical and Roche.